{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T03:17:10Z","timestamp":1791083830760,"version":"4.1.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"am","delay-in-days":336,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002674","name":"Russian Academy of Sciences","doi-asserted-by":"publisher","award":["MLN-4760"],"award-info":[{"award-number":["MLN-4760"]}],"id":[{"id":"10.13039\/501100002674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002674","name":"Russian Academy of Sciences","doi-asserted-by":"publisher","award":["1\\u20137"],"award-info":[{"award-number":["1\\u20137"]}],"id":[{"id":"10.13039\/501100002674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002674","name":"Russian Academy of Sciences","doi-asserted-by":"publisher","award":["29,30,81"],"award-info":[{"award-number":["29,30,81"]}],"id":[{"id":"10.13039\/501100002674","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL118650"],"award-info":[{"award-number":["HL118650"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL129727"],"award-info":[{"award-number":["HL129727"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL149808"],"award-info":[{"award-number":["HL149808"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["BX004356"],"award-info":[{"award-number":["BX004356"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL111437"],"award-info":[{"award-number":["HL111437"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000968","name":"American Heart Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000968","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"University of California, Los Angeles","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.ejmech.2022.114121","type":"journal-article","created":{"date-parts":[[2022,1,13]],"date-time":"2022-01-13T02:26:41Z","timestamp":1642040801000},"page":"114121","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"special_numbering":"C","title":["Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9068-6349","authenticated-orcid":false,"given":"Vanna","family":"Sanna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0827-8862","authenticated-orcid":false,"given":"Sandro","family":"Satta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1734-0792","authenticated-orcid":false,"given":"Tzung","family":"Hsiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2983-6090","authenticated-orcid":false,"given":"Mario","family":"Sechi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114121_bib1","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/s41564-020-0695-z","article-title":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2","volume":"5","author":"Gorbalenya","year":"2020","journal-title":"Nat. Microbiol."},{"key":"10.1016\/j.ejmech.2022.114121_bib2","series-title":"Naming the Coronavirus Disease (COVID-19) and the Virus that Causes it","author":"World Health Organization","year":"2020"},{"key":"10.1016\/j.ejmech.2022.114121_bib3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A\u00a0new coronavirus associated with human respirator disease in China","volume":"579","author":"Wu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114121_bib4","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A\u00a0novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114121_bib5","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1021\/acsinfecdis.0c00224","article-title":"COVID-19: living through another pandemic","volume":"6","author":"Osman","year":"2020","journal-title":"ACS Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114121_bib6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/s41591-021-01291-z","article-title":"Preparing for the next pandemic","volume":"27","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114121_bib7","doi-asserted-by":"crossref","first-page":"3647","DOI":"10.1039\/D0CS01118E","article-title":"Antiviral drug discovery: preparing for the next pandemic","volume":"50","author":"Adamson","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2022.114121_bib8","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/s41591-021-01282-0","article-title":"Developing therapeutic approaches for twenty-first-century emerging infectious viral diseases","volume":"27","author":"Meganck","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2022.114121_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/d41573-020-00016-0","article-title":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)","volume":"19","author":"Li","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114121_bib10","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1002\/cmdc.202000223","article-title":"Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics","volume":"15","author":"Ghosh","year":"2020","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2022.114121_bib11","doi-asserted-by":"crossref","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","article-title":"COVID-19: drug targets and potential treatments","volume":"63","author":"Gil","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib12","first-page":"668","article-title":"Recent discovery and development of inhibitors targeting coronaviruses, Drug Discov","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Today Off."},{"key":"10.1016\/j.ejmech.2022.114121_bib13","doi-asserted-by":"crossref","first-page":"12256","DOI":"10.1021\/acs.jmedchem.0c00502","article-title":"Inhibitors of SARS-CoV-2 entry: current and future opportunities","volume":"63","author":"Xiu","year":"2020","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib14","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/d41573-021-00037-3","article-title":"Trends in COVID-19 therapeutic clinical trials","volume":"20","author":"Bugin","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114121_bib15","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/d41586-021-03074-5","article-title":"COVID antiviral pill: what scientists still want to know","volume":"599","author":"Ledford","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114121_bib16","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1126\/science.abc1560","article-title":"Structural basis for inhibition of the RNA-dependent RNA polymerase from SARS-CoV-2 by remdesivir","volume":"368","author":"Yin","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114121_bib17","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1056\/NEJMe2018715","article-title":"Remdesivir - an important first step","volume":"383","author":"Dolin","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114121_bib18","article-title":"Remdesivir emergency Use authorization","year":"2020","journal-title":"Gilead Sci., Inc."},{"key":"10.1016\/j.ejmech.2022.114121_bib19","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1056\/NEJMoa2007016","article-title":"Compassionate use of remdesivir for patients with severe Covid-19","volume":"382","author":"Grein","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114121_bib20","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa2007764","article-title":"Remdesivir for the treatment of Covid-19 - final report","volume":"383","author":"Beigel","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114121_bib22","doi-asserted-by":"crossref","first-page":"1962","DOI":"10.1093\/jac\/dkab093","article-title":"Clinical efficacy and safety of remdesivir in patients with COVID-19: a systematic review and network meta-analysis of randomized controlled trials","volume":"76","author":"Lai","year":"2021","journal-title":"J.\u00a0Antimicrob. Chemother."},{"key":"10.1016\/j.ejmech.2022.114121_bib88","article-title":"Early remdesivir to prevent progression to severe Covid-19 in outpatients","author":"Gottlieb","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114121_bib23","doi-asserted-by":"crossref","first-page":"655","DOI":"10.3390\/ph14070655","article-title":"ADME and pharmacokinetic properties of remdesivir: its drug interaction potential","volume":"14","author":"Deb","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2022.114121_bib24","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3390\/pharmaceutics12111002","article-title":"Development of remdesivir as a dry powder for inhalation by thin film freezing","volume":"12","author":"Sahakijpijarn","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2022.114121_bib25","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1208\/s12248-020-00459-8","article-title":"Remdesivir for treatment of COVID-19: combination of pulmonary and IV administration may offer additional benefit","volume":"22","author":"Sun","year":"2020","journal-title":"AAPS J."},{"key":"10.1016\/j.ejmech.2022.114121_bib89","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.2217\/nnm-2020-0475","article-title":"Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in\u00a0vitro","volume":"16","author":"Vartak","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejmech.2022.114121_bib27","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2147\/IJN.S4937","article-title":"Nanomedicine in pulmonary delivery","volume":"4","author":"Mansour","year":"2009","journal-title":"Int. J. Nanomed."},{"key":"10.1016\/j.ejmech.2022.114121_bib28","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.2174\/1381612821666150923095742","article-title":"Nano-therapeutics for the lung: state-of-the-art and future perspectives","volume":"21","author":"Iyer","year":"2015","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.ejmech.2022.114121_bib29","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1002\/wnan.1401","article-title":"Polymeric nanoparticles in development for treatment of pulmonary infectious diseases","volume":"8","author":"Lim","year":"2016","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.ejmech.2022.114121_bib30","doi-asserted-by":"crossref","first-page":"119671","DOI":"10.1016\/j.ijpharm.2020.119671","article-title":"Inhaled nanoparticles-An updated review","volume":"587","author":"Praphawatvet","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ejmech.2022.114121_bib31","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/acsmedchemlett.0c00075","article-title":"Therapeutic potential of targeted nanoparticles and perspective on nanotherapies","volume":"11","author":"Sanna","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114121_bib32","doi-asserted-by":"crossref","first-page":"11147","DOI":"10.1021\/acs.chemrev.5b00116","article-title":"Clinical translation of nanomedicine","volume":"115","author":"Min","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ejmech.2022.114121_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.cell.2020.02.001","article-title":"Targeting strategies for tissue-specific drug delivery","volume":"181","author":"Zhao","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114121_bib34","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/nature02145","article-title":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus","volume":"426","author":"Li","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114121_bib35","doi-asserted-by":"crossref","first-page":"8722","DOI":"10.1128\/JVI.00253-07","article-title":"Clathrin-dependent entry of severe acute respiratory syndrome coronavirus into target cells expressing ACE2 with the cytoplasmic tail deleted","volume":"81","author":"Inoue","year":"2007","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.ejmech.2022.114121_bib36","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ejmech.2022.114121_bib37","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.cell.2020.03.045","article-title":"Structural and functional basis of SARS-CoV-2 entry by using human ACE2","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114121_bib38","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114121_bib39","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114121_bib40","doi-asserted-by":"crossref","first-page":"33238","DOI":"10.1074\/jbc.M002615200","article-title":"A\u00a0human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril insensitive carboxypeptidase","volume":"275","author":"Tipnis","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib41","doi-asserted-by":"crossref","first-page":"13185","DOI":"10.1021\/bi035268s","article-title":"Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence","volume":"42","author":"Guy","year":"2003","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114121_bib42","doi-asserted-by":"crossref","first-page":"2851","DOI":"10.1042\/CS20200899","article-title":"ACE2 and ACE: structure-based insights into mechanism, regulation and receptor recognition by SARS-CoV","volume":"134","author":"Lubbe","year":"2020","journal-title":"Clin. Sci."},{"key":"10.1016\/j.ejmech.2022.114121_bib43","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/nrcardio.2014.59","article-title":"Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets","volume":"11","author":"Jiang","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ejmech.2022.114121_bib44","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1530\/JOE-12-0341","article-title":"Angiotensin-converting enzyme 2, angiotensin-(1-7) and Mas: new players of the renin-angiotensin system","volume":"216","author":"Santos","year":"2013","journal-title":"J.\u00a0Endocrinol."},{"key":"10.1016\/j.ejmech.2022.114121_bib45","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/hr.2009.74","article-title":"Devil and angel in the renin-angiotensin system: ACE-angiotensin II-AT1 receptor axis vs. ACE2-angiotensin-(1\u20137)-Mas receptor axis","volume":"32","author":"Iwai","year":"2009","journal-title":"Hypertens. Res."},{"key":"10.1016\/j.ejmech.2022.114121_bib46","doi-asserted-by":"crossref","first-page":"588618","DOI":"10.3389\/fmolb.2020.588618","article-title":"ACE2 in the era of SARS-CoV-2: controversies and novel perspectives","volume":"7","author":"Saponaro","year":"2020","journal-title":"Front. Mol. Biosci."},{"key":"10.1016\/j.ejmech.2022.114121_bib47","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.3390\/cells9071704","article-title":"The Yin and Yang of ACE\/ACE2 pathways: the rationale for the use of renin-angiotensin system inhibitors in COVID-19 patients","volume":"9","author":"Zamai","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2022.114121_bib48","doi-asserted-by":"crossref","first-page":"30113","DOI":"10.1074\/jbc.M505111200","article-title":"Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)","volume":"280","author":"Lambert","year":"2005","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib49","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.1073\/pnas.0711241105","article-title":"Modulation of TNF-\u03b1-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-\u03b1-production and facilitates viral entry","volume":"105","author":"Haga","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114121_bib50","doi-asserted-by":"crossref","first-page":"576745","DOI":"10.3389\/fimmu.2020.576745","article-title":"ACE2\/ADAM17\/TMPRSS2 interplay may be the main risk factor for COVID-19","volume":"11","author":"Zipeto","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2022.114121_bib51","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1152\/physrev.00023.2016","article-title":"The ACE2\/Angiotensin-(1-7)\/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)","volume":"98","author":"Santos","year":"2018","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2022.114121_bib52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ejim.2020.04.037","article-title":"The pivotal link between ACE2 deficiency and SARS-CoV-2 infection","volume":"76","author":"Verdecchia","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"10.1016\/j.ejmech.2022.114121_bib53","doi-asserted-by":"crossref","first-page":"18579","DOI":"10.1074\/jbc.RA120.015303","article-title":"High affinity binding of SARS-CoV-2 spike protein enhances ACE2 carboxypeptidase activity","volume":"295","author":"Lu","year":"2020","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib54","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41422-020-00450-0","article-title":"Dalbavancin binds ACE2 to block its interaction with SARS-CoV-2 spike protein and is effective in inhibiting SARS-CoV-2 infection in animal models","volume":"31","author":"Wang","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2022.114121_bib55","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1165\/rcmb.2020-0322PS","article-title":"Targeting ACE2 for COVID-19 therapy: opportunities and challenges","volume":"64","author":"Jia","year":"2021","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114121_bib56","doi-asserted-by":"crossref","first-page":"11852","DOI":"10.1021\/ja0277226","article-title":"Substrate based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors","volume":"124","author":"Dales","year":"2002","journal-title":"J.\u00a0Am. Chem. Soc."},{"key":"10.1016\/j.ejmech.2022.114121_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ejphar.2016.01.007","article-title":"Angiotensin converting enzyme versus angiotensin converting enzyme-2 selectivity of MLN-4760 and DX600 in human and murine bone marrow-derived cells","volume":"774","author":"Joshi","year":"2016","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114121_bib58","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1021\/jm1013715","article-title":"Targeted biocompatible nanoparticles for the delivery of (-)-epigallocatechin 3-gallate to prostate cancer cells","volume":"54","author":"Sanna","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib59","doi-asserted-by":"crossref","first-page":"5209","DOI":"10.1021\/acs.jmedchem.5b01571","article-title":"Targeted nanoparticles for the delivery of novel bioactive molecules to pancreatic cancer cells","volume":"59","author":"Sanna","year":"2016","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib60","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/nrc2394","article-title":"Paul Ehrlich's magic bullet concept: 100 years of progress","volume":"8","author":"Strebhardt","year":"2008","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2022.114121_bib61","doi-asserted-by":"crossref","first-page":"10475","DOI":"10.1021\/acs.jmedchem.9b00511","article-title":"Precision cancer nanotherapy: evolving role of multifunctional nanoparticles for cancer active targeting","volume":"62","author":"Ahmad","year":"2019","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib62","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1021\/ar200054n","article-title":"Self-assembled targeted nanoparticles: evolution of technologies and bench to bedside translation","volume":"44","author":"Shi","year":"2011","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2022.114121_bib63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm800994j","article-title":"A\u00a0series of halogenated heterodimeric inhibitors of prostate specific membrane antigen (PSMA) as radiolabeled probes for targeting prostate cancer","volume":"52","author":"Maresca","year":"2009","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib64","doi-asserted-by":"crossref","first-page":"41573","DOI":"10.1038\/srep41573","article-title":"Targeted nanoparticles encapsulating (-)-epigallocatechin-3-gallate for prostate cancer prevention and therapy","volume":"7","author":"Sanna","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2022.114121_bib65","doi-asserted-by":"crossref","first-page":"12590","DOI":"10.1073\/pnas.1735443100","article-title":"The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy","volume":"100","author":"Sch\u00fclke","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.ejmech.2022.114121_bib66","doi-asserted-by":"crossref","first-page":"8718","DOI":"10.1021\/bi049480n","article-title":"Structural details on the binding of antihypertensive drugs captopril and enalaprilat to human testicular angiotensin I-converting enzyme","volume":"43","author":"Natesh","year":"2004","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2022.114121_bib67","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.antiviral.2009.12.001","article-title":"TACE antagonists blocking ACE2 shedding caused by the spike protein of SARS-CoV are candidate antiviral compounds","volume":"85","author":"Haga","year":"2010","journal-title":"Antivir. Res."},{"key":"10.1016\/j.ejmech.2022.114121_bib68","doi-asserted-by":"crossref","first-page":"17996","DOI":"10.1074\/jbc.M311191200","article-title":"ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis","volume":"279","author":"Towler","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib69","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/protein\/gzj014","article-title":"Stabilization of the autoproteolysis of TNF-alpha converting enzyme (TACE) results in a novel crystal form suitable for structure-based drug design studies","volume":"19","author":"Ingram","year":"2006","journal-title":"Protein Eng. Des. Sel."},{"key":"10.1016\/j.ejmech.2022.114121_bib70","doi-asserted-by":"crossref","first-page":"3849","DOI":"10.1021\/jo960057x","article-title":"Reductive amination of aldehydes and ketones with sodium triacetoxyborohydride. studies on direct and indirect reductive amination procedures (1)","volume":"61","author":"Abdel-Magid","year":"1996","journal-title":"J.\u00a0Org. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib71","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1186\/1556-276X-6-260","article-title":"Novel docetaxel-loaded nanoparticles based on poly(lactide-cocaprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization and cytotoxicity studies","volume":"6","author":"Sanna","year":"2011","journal-title":"Nanoscale Res. Lett."},{"key":"10.1016\/j.ejmech.2022.114121_bib72","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/978-1-59745-483-4_37","article-title":"Formulation\/preparation of functionalized nanoparticles for in\u00a0vivo targeted drug delivery","volume":"544","author":"Gu","year":"2009","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.ejmech.2022.114121_bib73","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0169-409X(02)00226-0","article-title":"PEGylated nanoparticles for biological and pharmaceutical applications","volume":"55","author":"Otsuka","year":"2003","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2022.114121_bib74","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.jconrel.2016.06.017","article-title":"DLS and zeta potential. What they are and what they are not?","volume":"235","author":"Bhattacharjee","year":"2016","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.ejmech.2022.114121_bib75","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1161\/STROKEAHA.120.032764","article-title":"Flow mediated susceptibility and molecular response of cerebral endothelia to SARS-CoV-2 infection","volume":"52","author":"Kaneko","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.ejmech.2022.114121_bib76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jviromet.2008.03.006","article-title":"Development of a high-throughput Alamar blue assay for the determination of influenza virus infectious dose, serum antivirus neutralization titer and virus ca\/ts phenotype","volume":"150","author":"Mo","year":"2008","journal-title":"J.\u00a0Virol. Methods"},{"key":"10.1016\/j.ejmech.2022.114121_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ijid.2020.05.085","article-title":"Lack of antiviral activity of darunavir against SARS-CoV-2","volume":"97","author":"De Meyer","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.ejmech.2022.114121_bib78","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1002\/(SICI)1521-3773(19981102)37:20<2754::AID-ANIE2754>3.0.CO;2-3","article-title":"Polyvalent interactions in biological systems: implications for design and use of multivalent ligands and inhibitors","volume":"37","author":"Mammen","year":"1998","journal-title":"Angew. Chem. Int. Ed."},{"key":"10.1016\/j.ejmech.2022.114121_bib79","doi-asserted-by":"crossref","first-page":"3409","DOI":"10.1039\/b413971b","article-title":"Multivalency in supramolecular chemistry and nanofabrication","volume":"2","author":"Mulder","year":"2004","journal-title":"Org. Biomol. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib80","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1021\/ar040223k","article-title":"Multivalency and cooperativity in supramolecular chemistry","volume":"38","author":"Badji\u0107","year":"2005","journal-title":"Acc. Chem. Res."},{"key":"10.1016\/j.ejmech.2022.114121_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax5866","article-title":"Characterization of orally efficacious influenza drug with high resistance barrier in ferrets and human airway epithelia","volume":"11","author":"Toots","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ejmech.2022.114121_bib82","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jconrel.2021.07.028","article-title":"Repurpose but also (nano)-reformulate! the potential role of nanomedicine in the battle against SARS-CoV2","volume":"337","author":"Tammam","year":"2021","journal-title":"J.\u00a0Contr. Release"},{"key":"10.1016\/j.ejmech.2022.114121_bib83","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J.\u00a0Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib84","doi-asserted-by":"crossref","first-page":"111621","DOI":"10.1016\/j.ejmech.2019.111621","article-title":"Discovery of novel functionalized 1,2,4-triazoles as PARP-1 inhibitors in breast cancer: design, synthesis and antitumor activity evaluation","volume":"182","author":"Boraei","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114121_bib85","first-page":"221","article-title":"Molecular dynamics and pharmacophore modeling studies of different subtype (ALK and EGFR (T790M)) inhibitors in NSCLC. SAR QSAR","volume":"28","author":"Singh","year":"2017","journal-title":"Environ. Res."},{"key":"10.1016\/j.ejmech.2022.114121_bib86","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1021\/acsmedchemlett.5b00109","article-title":"Virtual screening and biological validation of novel influenza virus PA endonuclease inhibitors","volume":"6","author":"Pala","year":"2015","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114121_bib87","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J.\u00a0Comput. Chem."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342200023X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S022352342200023X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:02:12Z","timestamp":1777528932000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S022352342200023X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":87,"alternative-id":["S022352342200023X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114121","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of targeted nanoparticles loaded with antiviral drugs for SARS-CoV-2 inhibition","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114121","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114121"}}